Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study
暂无分享,去创建一个
M. Taskinen | D. Gordin | C. Forsblom | P. Groop | N. Sandholm | V. Harjutsalo | L. Thorn | J. Wadén | N. Tolonen | V. Mäkinen | M. Feodoroff
[1] M. Taskinen,et al. Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the FinnDiane Study , 2013, Journal of internal medicine.
[2] Jeroen J. Bax,et al. Third universal definition of myocardial infarction , 2013, Nature Reviews Cardiology.
[3] N. Sattar,et al. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? , 2013, Diabetologia.
[4] Bernadette A. Thomas,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[5] V. Basevi. Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.
[6] T. Lüscher,et al. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.
[7] A. Zwinderman,et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. , 2012, JAMA.
[8] Yining Huang,et al. Nonenzymatic glycation of high‐density lipoprotein impairs its anti‐inflammatory effects in innate immunity , 2012, Diabetes/metabolism research and reviews.
[9] K. Michaëlsson,et al. Useful tests of usefulness of new risk factors: Tools for assessing reclassification and discrimination , 2011, Scandinavian journal of public health.
[10] R. G. Miller,et al. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2010, Diabetologia.
[11] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[12] Merlin C. Thomas,et al. The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.
[13] K. Tan,et al. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] M. Taskinen,et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes , 2007, Diabetologia.
[15] P. Gambert,et al. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation , 2007, Diabetologia.
[16] P. Barter,et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase , 2007, Diabetologia.
[17] S. Soedamah-Muthu,et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. , 2006, Diabetes care.
[18] Merlin C. Thomas,et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.
[19] R. Rabini,et al. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.
[20] N. Chaturvedi,et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. , 2004, Diabetes care.
[21] Tracey McLaughlin,et al. Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant , 2003, Annals of Internal Medicine.
[22] C. Packard,et al. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. , 2003, Biochemical Society transactions.
[23] K. Forrest,et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. , 2003, Diabetes care.
[24] M. Taskinen,et al. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. , 2001, Diabetes Care.
[25] S M Grundy,et al. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. , 2001, Circulation.
[26] S. Bandinelli,et al. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[27] T. Orchard,et al. Can clinical factors estimate insulin resistance in type 1 diabetes? , 2000, Diabetes.
[28] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[29] M. Laakso,et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.
[30] J. Hokanson,et al. Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.
[31] M. Taskinen,et al. Regulation of Apolipoprotein A-I–Containing Lipoproteins in IDDM , 1993, Diabetes.
[32] M. Taskinen. Quantitative and Qualitative Lipoprotein Abnormalities in Diabetes Mellitus , 1992, Diabetes.
[33] J. Holst,et al. Glucagon Immunoneutralization in Diabetic Rats Normalizes Urea Synthesis and Decreases Nitrogen Wasting , 1992, Diabetes.
[34] K. Borch-Johnsen,et al. Coronary heart disease in young Type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors , 1987, Diabetologia.
[35] J. Neaton,et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.
[36] P. Durrington,et al. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. , 1978, Clinica chimica acta; international journal of clinical chemistry.
[37] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[38] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2015 .
[39] H. Hammes,et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD , 2013 .
[40] A. Jaffe. Third universal definition of myocardial infarction. , 2013, Clinical biochemistry.
[41] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .
[42] D. Power. Standards of medical care in diabetes. , 2006, Diabetes care.
[43] A. Sniderman,et al. Putting low-density lipoproteins at center stage in atherogenesis. , 1997, The American journal of cardiology.
[44] Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. , 1995, The American journal of cardiology.